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We have recently reported that CYB5D2 plays a role in suppression
of cervical cancer tumorigenesis, “CYB5D2 displays tumor sup-
pression activities towards cervical cancer” [1]. We provide the
accompany data here describing the effects of CYB5D2 over-
expression and addition of recombinant CYB5D2 on HeLa cell cycle
distribution. Furthermore, we will present the conditions used to
speciﬁcally determine CYB5D2 expression in primary cervical and
cervical cancer tissues using immunohistochemistry (IHC) and the
patient cohort involved in assessing the CYB5D2 protein levels in
primary cervical and cervical cancer tissues.
& 2016 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).vier Inc. This is an open access article under the CC BY license
/j.bbadis.2015.12.013
gy, Department of Medicine, McMaster University, Canada.
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featuresCell cycle progression and protein expressionata source
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Value of the data
 CYB5D2's effects on HeLa cell cycle distribution could be considered when investigating a role of
CYB5D2 in regulating cell proliferation in other cell types.
 The data on CYB5D2 in affecting ERK and AKT activation should be helpful in researching CYB5D2's
role in regulating growth factor receptor signaling.
 The data is useful for future investigations of CYB5D2-mediated cellular processes.1. Data
Fig. 1 examines the cell cycle distribution of HeLa cells stably expressing either an empty vector
(HeLa EV) or CYB5D2 (HeLa CYB5D2).
Fig. 2 shows the status of AKT and ERK1/2 activation in HeLa EV and HeLa CYB5D2 cells. Activation
of AKT and ERK1/2 was indirectly determined according to the speciﬁc phosphorylation events (see
Fig. 2 legend for details).ffects of CYB5D2 overexpression on HeLa cell cycle distribution. HeLa EV and HeLa CYB5D2 cells
s, and cultured for 2 days. At density of approximately 80% conﬂuency, cell cycle distributions were
ometer.
Fig. 2. The impacts of ectopic expression of CYB5D2 on serum-induced activation of AKT and ERK kinases. HeLa EV and HeLa
CYB5D2 cells at approximately 90% conﬂuency were serum starved for 24 h, and stimulated with 10% of fetal bovine serum for
the indicated periods, followed by western blot analysis for the phosphorylation of AKT at serine 473 (pAKT) and ERK at
threonine 183 and tyrosine 185 (pERK1/2) as well as CYB5D2 and GAPDH. Experiments were performed twice; typical results
from a single repeat are shown. SF: serum free.
Fig. 3. Determination of the effects of recombinant CYB5D2 on HeLa cell cycle distribution. GST and GST-CYB5D2 recombinant
proteins were puriﬁed from E. coli. HeLa EV and HeLa CYB5D2 cells were incubated with GST and GST-CYB5D2 at 1 mg/ml for
24 h, followed by the determination of cell cycle distribution. Cell proliferation in the presence of either protein was clearly
observed. Experiments were carried out twice; typical results from a single repeat are shown.
Fig. 4. Anti-CYB5D2 antibody speciﬁcally recognizes CYB5D2. Normal human kidney tissue was immunohistochemistry (IHC)
stained with anti-CYB5D2 antibody without and with addition of recombinant GST-CYB5D2 or GST. The indicated regions were
enlarged 3 fold and presented underneath of the individual panels. Recombinant GST-CYB5D2 and GST were produced in E. coli
BL21. The recombinant protein GST-CYB5D2 was generated by N-terminal fusion of the transmembrane domain deletion
mutant of CYB5D2 to GST. Anti-CYB5D2 antibody was afﬁnity-puriﬁed by using GST-CYB5D2 as previously described [4]. For
the competition experiments, GST-CYB5D2 or GST at 1 mg/ml was pre-incubated for one hour on ice with anti-CYB5D2
antibody (1:250) before applying to human kidney tissues.
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Table 1
Patient's clinical information.
Patients Pathological diagnosis Age Grade
1 Endocervical type adenocarcinoma 42 1
2 Endocervical type adenocarcinoma 42 1
3 Endometrioid adenocarcinoma with squamous
metaplasia
48 1
4 Endometrioid adenocarcinoma with squamous
metaplasia
48 1
5 Endocervical type adenocarcinoma 52 1–2
6 Endocervical type adenocarcinoma 52 1–2
7 Endometrioid adenocarcinoma 32 1–2
8 Endometrioid adenocarcinoma 32 1–2
9 Instestinal type adenocarcinoma 72 2
10 Instestinal type adenocarcinoma 72 2
11 Endocervical type adenocarcinoma 43 2
12 Endocervical type adenocarcinoma 43 2
13 Clear cell adenocarcinoma 40 –
14 Clear cell adenocarcinoma 40 –
15 Instestinal type adenocarcinoma 51 2
16 Instestinal type adenocarcinoma 51 2–3
17 Endocervical type adenocarcinoma 50 2–3
18 Endocervical type adenocarcinoma 50 2–3
19 Instestinal type adenocarcinoma 34 2
20 Instestinal type adenocarcinoma 34 2
21 Adenocarcinoma 44 3
22 Adenocarcinoma 44 3
23 Adenocarcinoma 52 3
24 Adenocarcinoma 52 3
25 Adenocarcinoma 59 3
26 Adenocarcinoma 59 3
27 Endometrioid adenocarcinoma 26 3
28 Endometrioid adenocarcinoma 26 3
29 Adenocarcinoma (ﬁbrous tissue and blood vessel) 32 –
30 Adenocarcinoma (ﬁbrous tissue and blood vessel) 32 –
31 Adenosquamous carcinoma 43 –
32 Adenosquamous carcinoma 43 –
33 Adenosquamous carcinoma 64 –
34 Adenosquamous carcinoma 64 –
35 Adenosquamous carcinoma 38 –
36 Adenosquamous carcinoma 38 –
37 Adenosquamous carcinoma 54 –
38 Adenosquamous carcinoma 54 –
39 Adenosquamous carcinoma 43 –
40 Adenosquamous carcinoma 43 –
41 Squamous cell carcinoma 53 2
42 Squamous cell carcinoma 53 2
43 Squamous cell carcinoma 27 2
44 Squamous cell carcinoma 27 2
45 Squamous cell carcinoma 68 2–3
46 Squamous cell carcinoma 68 2–3
47 Squamous cell carcinoma 37 3
48 Squamous cell carcinoma 37 3
49 Squamous cell carcinoma 43 3
50 Squamous cell carcinoma 43 3
51 Squamous cell carcinoma 69 2
52 Squamous cell carcinoma with necrosis 69 2
53 Squamous cell carcinoma (sparse) 48 2
54 Squamous cell carcinoma 48 2
55 Squamous cell carcinoma 36 3
56 Squamous cell carcinoma 36 3
57 Squamous cell carcinoma 63 2
58 Squamous cell carcinoma 63 2
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Table 1 (continued )
Patients Pathological diagnosis Age Grade
59 Squamous cell carcinoma 47 2
60 Squamous cell carcinoma 47 1–2
61 Squamous cell carcinoma 40 2
62 Squamous cell carcinoma 40 2
63 Squamous cell carcinoma 76 2
64 Squamous cell carcinoma 76 2
65 Squamous cell carcinoma 38 3
66 Squamous cell carcinoma (ﬁbrous tissue and blood
vessel)
38 –
67 Squamous cell carcinoma 36 2–3
68 Squamous cell carcinoma 36 2–3
69 Squamous cell carcinoma 62 3
70 Squamous cell carcinoma 62 3
71 Squamous cell carcinoma 51 3
72 Squamous cell carcinoma 51 3
73 Squamous cell carcinoma 32 3
74 Squamous cell carcinoma 32 3
75 Squamous cell carcinoma 58 3
76 Squamous cell carcinoma 58 3
77 Squamous cell carcinoma 27 3
78 Squamous cell carcinoma 27 3
79 Squamous cell carcinoma 39 2
80 Squamous cell carcinoma 39 3
81 Cancer adjacent normal cervical tissue 45 –
82 Cancer adjacent normal cervical tissue 45 –
83 Cancer adjacent normal cervical canals tissue 62 –
84 Cancer adjacent normal cervical canals tissue 62 –
85 Cancer adjacent normal cervical canals tissue 50 –
86 Cancer adjacent normal cervical canals tissue 50 –
87 Cancer adjacent normal cervical tissue of No 13 40 –
88 Cancer adjacent normal cervical tissue of No 13 40 –
89 Cancer adjacent normal cervical tissue (ﬁbrous tissue
and blood vessel)
60 –
90 Cancer adjacent normal cervical tissue 60 –
91 Normal cervical tissue 18 –
92 Normal cervical tissue 18 –
93 Normal cervical tissue 15 –
94 Normal cervical tissue 15 –
95 Normal cervical tissue (ﬁbrous tissue and blood vessel) 21 –
96 Normal cervical tissue (ﬁbrous tissue and blood vessel) 21 –
97 Normal cervical tissue (with hyperplasia of glandular
epithelium)
21 –
98 Normal cervical tissue (with hyperplasia of glandular
epithelium)
21 –
99 Normal cervical tissue (ﬁbrous tissue and blood vessel) 19 –
100 Normal cervical tissue (ﬁbrous tissue and blood vessel) 19 –
Y. Xie et al. / Data in Brief 6 (2016) 811–816 815CYB5D2 can be a secretory protein [2,3] that has been indicated to inhibit Neuro2a cell pro-
liferation [2]. The cell cycle distribution of HeLa cells was determined in the presence of either GST or
GST-CYB5D2 (Fig. 3).
Fig. 4 shows recognition of the CYB5D2 protein in human kidney tissues by the anti-CYB5D2
antibody in the presence of GST or GST-CYB5D2 as a competitor.
Table 1 shows the tissues used to examine the CYB5D2 protein levels in normal cervical and
cervical cancer tissues.
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2.1. Experimental design and subjects
A tissue microarray slide was selected from US Biomax that contained 40 cervical squamous cell
carcinoma and 20 normal cervical tissues (Table 1). HeLa cells stably expressing EV or CYB5D2 were
recently constructed [1,4].
2.2. Cell cycle distribution determination
Cell cycle distribution was determined by individualizing cells using 0.02% EDTA in PBS. Cells were
stained with a propidium iodide (PI) solution (10 mM Tris pH7.5, 150 mM NaCl, 0.05 mg/ml PI, 0.1%
sodium citrate, 0.2% Triton X-100, and 0.2 mg/ml DNase-free RNase A) overnight at 4 °C in dark.Cell
cycle distribution was analyzed using a ﬂuorescent automated cell sorting (FACS) (Bechman Coulter,
CytomicsTM FC500).Acknowledgments
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